# Bristol Myers Squibb Co (BMY)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/bristol-myers-squibb-co/ JSON: https://steadybase.io/company/bristol-myers-squibb-co.json Checked Nov 10, 2026. Latest filing read: Oct 29, 2026.

## Company

- Legal name: BRISTOL MYERS SQUIBB CO
- Ticker: BMY, CELG-RI (NYSE, NYSE)
- SEC CIK: 0000014272
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: Princeton, NJ
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: bms.com
- Investor relations: https://www.bms.com/investors.html
- LinkedIn: https://www.linkedin.com/company/bristol-myers-squibb
- Next earnings date: Jan 28, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $48.2B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/0000014272-26-000004-index.html
- Net income: $7.1B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/0000014272-26-000004-index.html
- SG&A: $7.3B for the fiscal year ended Dec 31, 2025 (10-K filed Feb 11, 2026). Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/0000014272-26-000004-index.html
- Employees: 32,500 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/0000014272-26-000004-index.html
- Shares outstanding: 2,044,085,831 as of Oct 21, 2026 (10-Q filed Oct 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/0000014272-26-000024-index.html
- Auditor: Deloitte & Touche LLP, Morristown, New Jersey, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm

## Business

Bristol-Myers Squibb Company ("we", the "Company", "Bristol Myers Squibb", or "BMS") was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Net income | SG&A |
|---|---|---|---|
| Dec 31, 2025 | $48.2B | $7.1B | $7.3B |
| Dec 31, 2024 | $48.3B | -$8.9B | $8.4B |
| Dec 31, 2023 | $45.0B | $8.0B | $7.8B |
| Dec 31, 2022 | $46.2B | $6.3B | $7.8B |
| Dec 31, 2021 | $46.4B | $7.0B | $7.7B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/bristol-myers-squibb-co.json

## Officers and directors

- Christopher S. Boerner, Chief Executive Officer. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/14272/000154374726000002/0001543747-26-000002-index.htm
- David Elkins V., EVP, Chief Financial Officer. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/14272/000145160426000004/0001451604-26-000004-index.htm
- David V. Elkins, Chief Financial Officer (Principal Financial Officer). LinkedIn: https://linkedin.com/in/david-elkins-b8981377. Source: 10-K filed Feb 11, 2026, https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm
- Benjamin Hickey, President, RayzeBio Org.. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/14272/000175305526000006/0001753055-26-000006-index.htm
- Lynelle Hoch, President, Cell Therapy Org.. LinkedIn: https://linkedin.com/in/lynelle-hoch-19887994. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/14272/000200538226000002/0002005382-26-000002-index.htm
- Cristian Massacesi, EVP,Chief Med Offr,Head of Dev. Source: Form 4 filed Sep 10, 2026, https://www.sec.gov/Archives/edgar/data/14272/000208017626000006/0002080176-26-000006-index.htm
- Bartie Wendy Short, EVP, Corporate Affairs. Source: Form 4 filed Sep 3, 2026, https://www.sec.gov/Archives/edgar/data/14272/000207083926000007/0002070839-26-000007-index.htm
- Phil M. Holzer, SVP and Controller. Source: Form 4 filed Aug 26, 2026, https://www.sec.gov/Archives/edgar/data/14272/000201258826000004/0002012588-26-000004-index.htm
- Cari Gallman, EVP, General Counsel. Source: Form 4 filed Aug 4, 2026, https://www.sec.gov/Archives/edgar/data/14272/000199505826000005/0001995058-26-000005-index.htm
- Adam Lenkowsky, EVP, Chief Commercial Officer. LinkedIn: https://linkedin.com/in/adam-lenkowsky-90750a11. Source: Form 4 filed May 5, 2026, https://www.sec.gov/Archives/edgar/data/14272/000197571926000004/0001975719-26-000004-index.htm
- Karin Shanahan, EVP, Chief Supply Chain & Ops. LinkedIn: https://linkedin.com/in/karin-shanahan-9263399. Source: Form 4 filed Apr 2, 2026, https://www.sec.gov/Archives/edgar/data/14272/000191732526000004/0001917325-26-000004-index.htm
- Ahn Amanda Poole, EVP, Chief People Officer. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/14272/000200521026000002/0002005210-26-000002-index.htm
- Gregory Scott Meyers, EVP, Chief Digital & Tech Off.. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/14272/000190876926000004/0001908769-26-000004-index.htm
- Hiroshi Chris Shibutani, EVP, Chief Strategy Officer. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/14272/000207249426000002/0002072494-26-000002-index.htm
- Robert M. Plenge, EVP, Chief Research Officer. LinkedIn: https://linkedin.com/in/robert-plenge-86560535. Source: Form 4 filed Mar 12, 2026, https://www.sec.gov/Archives/edgar/data/14272/000177336726000002/0001773367-26-000002-index.htm
- Christopher S. Boerner, Ph.D., Board member (per proxy). Source: DEF 14A filed Mar 25, 2026, https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm
- Cristian Massacesi, M.D., Named in proxy. LinkedIn: https://linkedin.com/in/cristian-massacesi. Source: DEF 14A filed Mar 25, 2026, https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm
- Greg Meyers, Named in proxy. Source: DEF 14A filed Mar 25, 2026, https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm
- Samit Hirawat, M.D., Named in proxy. Source: DEF 14A filed Mar 25, 2026, https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm

## Recent 8-K events

- Oct 29, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000022/bmy-20261029.htm
- Jul 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000018/bmy-20260730.htm
- May 8, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/14272/000114036126020036/ef20072750_8k.htm
- Apr 30, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000008/bmy-20260430.htm
- Feb 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427226000002/bmy-20260205.htm
- Jan 12, 2026: Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000114036126000929/ef20062582_8k.htm
- Nov 18, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000114036125042607/ef20059419_8k.htm
- Nov 10, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000114036125041380/ny20057651x6_8k.htm
- Nov 3, 2025: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000114036125040066/ef20058056_8k.htm
- Oct 30, 2025: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000147/bmy-20251030.htm

## Insider trades (Form 4)

- Nov 5, 2026: Julia A. Haller (Director) sold 3,800 shares, about $240,578. Source: https://www.sec.gov/Archives/edgar/data/14272/000165608226000006/0001656082-26-000006-index.htm
- Sep 9, 2026: Cristian Massacesi (EVP,Chief Med Offr,Head of Dev) sold 6,249 shares, about $403,498. Source: https://www.sec.gov/Archives/edgar/data/14272/000208017626000006/0002080176-26-000006-index.htm
- Aug 25, 2026: Phil M. Holzer (SVP and Controller) sold 500 shares, about $33,750. Source: https://www.sec.gov/Archives/edgar/data/14272/000201258826000004/0002012588-26-000004-index.htm
- Apr 1, 2026: David Elkins V. (EVP, Chief Financial Officer) sold 30,000 shares, about $1.9M. Source: https://www.sec.gov/Archives/edgar/data/14272/000145160426000004/0001451604-26-000004-index.htm
- Sep 2, 2025: David Elkins V. (EVP, Chief Financial Officer) sold 56,000 shares, about $2.7M. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000144/0000014272-25-000144-index.htm
- Aug 2, 2025: Bartie Wendy Short (EVP, Corporate Affairs) sold 378 shares, about $16,719. Source: https://www.sec.gov/Archives/edgar/data/14272/000001427225000133/0000014272-25-000133-index.htm

## Latest filings

- 8-K filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/14272/000001427226000022/bmy-20261029.htm
- 10-K filed Feb 11, 2026: https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm
- 10-Q filed Oct 29, 2026: https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- DEF 14A filed Mar 25, 2026: https://www.sec.gov/Archives/edgar/data/14272/000001427226000006/bmy-20260325.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/